Cabaletta Bio is set to commence a Phase I/II clinical trial of CABA-201 to treat systemic lupus erythematosus (SLE) in patients suffering from active lupus nephritis (LN) or active SLE without renal involvement.

The company’s decision comes after it secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy.

The clearance has been given within six months of in-licensing the CABA-201 binder.

SLE is a chronic, potentially severe, autoimmune disease that usually affects young women between the age group of 15 and 40.

In the proposed open label dose evaluation trial, patients will receive a standard preconditioning regimen comprising fludarabine and cyclophosphamide before CABA-201 infusion.

It will be the first trial to use Cabaletta’s Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) strategy, said the firm.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

Cabaletta Bio CEO and co-founder Steven Nichtberger said: “Based on its similarity to the product used in the Nature Medicine paper, we believe CABA-201 has the potential to provide deep and durable responses for patients with SLE, and possibly other autoimmune diseases where B cells play a role to initiate or sustain disease pathology.

“By achieving a timely IND clearance, we believe we are well positioned to generate three-month clinical data on efficacy endpoints and tolerability for patients dosed with CABA-201 by the first half of 2024.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell...

Read more

Thank you.

You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.